Evidence map›Paper›PMID 42283553›Full record

ArticleAntimicrobial agents and chemotherapy2026

Comparison of effectiveness and safety of cefoperazone-sulbactam versus ceftriaxone and flomoxef in acute cholangitis: a multicenter retrospective study.

Chieh-Chang Chen, Jiann-Hwa Chen, Wen-Hsin Huang, Tsung-Lin Hsieh, Li-Wei Chen, Ming-Chang Tsai, Nai-Jen Liu, Chi-Huan Wu, Chen-Shuan Chung, Yi-Chun Chiu and 6 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chieh-Chang ChenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-2953-210X
Jiann-Hwa ChenDivision of Gastroenterology and Hepatology, Taipei Tzu Chi Hospital, New Taipei City, Taiwan.
Wen-Hsin HuangCenter for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Tsung-Lin HsiehCenter for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Li-Wei ChenDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital and Chang Gung University at Keelung, Keelung, Taiwan.
Ming-Chang TsaiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
Nai-Jen LiuDepartment of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Chi-Huan WuDepartment of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Chen-Shuan ChungDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Yi-Chun ChiuDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chih-Ming LiangDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Cheng-Kun WuDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Wen-Lun WangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Ching-Tai LeeDivision of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Ming-Hung HsuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Hsiu-Po WangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-7741-9315

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute cholangitis is a potentially life-threatening biliary tract infection requiring prompt antibiotic therapy. Cefoperazone-sulbactam is a recommended option for mild-to-moderate disease, but comparative evidence versus ceftriaxone and flomoxef is limited. In this multicenter retrospective study, 389 adults with acute cholangitis from nine Taiwanese centers (January 2022-July 2024) received cefoperazone-sulbactam (

Indexed as

Anti-Bacterial AgentsCefoperazoneCeftriaxoneCephalosporinsCholangitisSulbactamAcute DiseaseAgedFemaleHumansMaleMiddle AgedRetrospective StudiesSecond Generation CephalosporinsThird Generation CephalosporinsTreatment OutcomeAnti-Bacterial AgentsCefoperazoneCeftriaxoneCephalosporinsflomoxefSecond Generation CephalosporinsSulbactamThird Generation Cephalosporinsacute cholangitisbiliary tract infectioncefoperazone–sulbactamceftriaxoneempirical antibioticsextended-spectrum β-lactamase (ESBL)flomoxef

Identifiers

PMID42283553
PMCPMC13321815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.